SCHEMBL508553

SCHEMBL508553

CC(Br)c1ccc(C(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.55
TP53 P04637 1/20 0.55
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KMT2A Q03164 1/20 0.50
SRD5A2 P31213 2/20 0.48
ANPEP P15144 1/20 0.47
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA12 O43570 1/20 0.46
CA3 P07451 1/20 0.46
TYR P14679 1/20 0.46
DRD1 P21728 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CA5B Q9Y2D0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL27719616 0.98 TSHR (0.52) TSHRTP53ALDH1A1SMN1; SMN2KMT2A
Ethylene Glycol SCHEMBL28157678 0.92 TP53 (0.46) TSHRTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL8322257 0.86 TSHR (0.42) TSHRTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL13898479 0.83 TSHR (0.50) TSHRTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL595998 0.82 MAPT (0.46) ALDH1A1SMN1; SMN2KMT2AHPGDMAPK1
SCHEMBL11612820 0.82 HDAC8 (0.42) ALDH1A1SMN1; SMN2KMT2ARXRARXRB
SCHEMBL372015 0.81 TSHR (0.60) TSHRTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL31192242 0.81 TSHR (0.60) TSHRTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL3980828 0.81 TSHR (0.60) TSHRTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL4642822 0.81 TSHR (0.60) TSHRTP53ALDH1A1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638706-A2 NANOFIBROUS SCAFFOLD FOR CELL CULTURING Cellevate AB (SE) 2025-10-29 EP claimed
CN-119504600-A Etomidate hapten as well as preparation method and application thereof 深圳市绿诗源生物技术有限公司 2025-02-25 CN claimed
WO-2024133700-A2 NANOFIBROUS SCAFFOLD FOR CELL CULTURING CELLEVATE AB (SE) 2024-06-27 WO claimed
CN-105348206-A Paclobutrazol semiantigen, antigen, antibody and preparation method WANG QIUYAN 2016-02-24 CN claimed
EP-4638706-A2 NANOFIBROUS SCAFFOLD FOR CELL CULTURING Cellevate AB (SE) 2025-10-29 EP disclosed
EP-4638707-A1 NANOFIBROUS SCAFFOLD FOR INDUSTRIAL SCALE CELL CULTURING Cellevate AB (SE) 2025-10-29 EP disclosed
US-12297302-B2 Amphiphilic compound, and medical resin composition and pharmaceutical additive using the same NIPPON SHOKUBAI CO., LTD. (JP) 2025-05-13 US disclosed
CN-119504600-A Etomidate hapten as well as preparation method and application thereof 深圳市绿诗源生物技术有限公司 2025-02-25 CN disclosed
US-20250041430-A1 CONJUGATE COMPOUND AND METHOD FOR PRODUCING CONJUGATE COMPOUND NIPPON SHOKUBAI CO., LTD. (JP) 2025-02-06 US disclosed
WO-2024133634-A1 NANOFIBROUS SCAFFOLD FOR INDUSTRIAL SCALE CELL CULTURING CELLEVATE AB (SE) 2024-06-27 WO disclosed
WO-2024133700-A2 NANOFIBROUS SCAFFOLD FOR CELL CULTURING CELLEVATE AB (SE) 2024-06-27 WO disclosed
US-20240116872-A1 PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING GENENTECH, INC. (US) 2024-04-11 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
US-6191171-B1 ANTAGONISTS, USEFUL IN INHIBITION OR PREVENTION OF CELL ADHESION AND CELL-ADHESION MEDIATED PATHOLOGIES; FOR DRUGS FOR TREATMENT OF ASTHMA, ALLERGIES, INFLAMMATION, MULTIPLE SCLEROSIS, AND OTHER INFLAMMATORY AND AUTOIMMUNE DISORDERS MERCK & CO., INC. 2001-02-20 US disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
WO-1999026923-A1 PARA-AMINOMETHYLARYL CARBOXAMIDE DERIVATIVES MERCK & CO., INC. (US) 1999-06-03 WO disclosed
EP-0874242-A1 Device and apparatus for the simultaneous detection of multiple analytes Randox Laboratories Ltd. (GB) 1998-10-28 EP disclosed
CN-1197452-A Azetidinone derivatives for treatment of atherosclerosis SMITHKLINE BEECHAM PLC (GB) 1998-10-28 CN disclosed
US-4578361-A Creatinine antibody BOEHRINGER MANNHEIM GMBH (DE) 1986-03-25 US disclosed
US-4543325-A Process and reagent for the determination of creatinine BOEHRINGER MANNHEIM GMBH (DE) 1985-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250041430-A1 CONJUGATE COMPOUND AND METHOD FOR PRODUCING CONJUGATE COMPOUND C9, C3AR1, C5AR1 TSHR 2885/4885TP53 3611/4885ALDH1A1 2220/4885
US-12297302-B2 Amphiphilic compound, and medical resin composition and pharmaceutical additive using the same LIPA, ABHD16A, ABCB11 TSHR 3598/4885TP53 2719/4885ALDH1A1 1842/4885
US-20240116872-A1 PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING SHH, GLI1, SMO TSHR 453/4885TP53 775/4885ALDH1A1 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.